Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinson Disease | 23 | 2024 | 180 | 3.670 |
Why?
|
| Antiparkinson Agents | 7 | 2023 | 21 | 1.300 |
Why?
|
| Deep Brain Stimulation | 8 | 2022 | 49 | 1.250 |
Why?
|
| Chorea | 3 | 2023 | 12 | 1.040 |
Why?
|
| Huntington Disease | 3 | 2023 | 28 | 1.020 |
Why?
|
| Levodopa | 5 | 2023 | 41 | 0.950 |
Why?
|
| Double-Blind Method | 13 | 2024 | 742 | 0.690 |
Why?
|
| Antipsychotic Agents | 3 | 2023 | 241 | 0.680 |
Why?
|
| Carbidopa | 2 | 2023 | 4 | 0.630 |
Why?
|
| Essential Tremor | 4 | 2020 | 10 | 0.620 |
Why?
|
| Thiazolidinediones | 1 | 2015 | 95 | 0.500 |
Why?
|
| Neuroprotective Agents | 1 | 2015 | 125 | 0.480 |
Why?
|
| Globus Pallidus | 3 | 2019 | 6 | 0.480 |
Why?
|
| Subthalamic Nucleus | 3 | 2019 | 13 | 0.470 |
Why?
|
| Food Preservatives | 1 | 2013 | 4 | 0.450 |
Why?
|
| Food Preservation | 1 | 2013 | 9 | 0.450 |
Why?
|
| Food Packaging | 1 | 2013 | 7 | 0.450 |
Why?
|
| Vegetables | 1 | 2013 | 73 | 0.430 |
Why?
|
| Anesthesia, General | 3 | 2018 | 96 | 0.420 |
Why?
|
| Creatine | 3 | 2017 | 38 | 0.410 |
Why?
|
| Fruit | 1 | 2013 | 142 | 0.410 |
Why?
|
| Treatment Outcome | 14 | 2024 | 5609 | 0.400 |
Why?
|
| Indans | 2 | 2023 | 9 | 0.370 |
Why?
|
| Tetrabenazine | 3 | 2023 | 12 | 0.370 |
Why?
|
| Wakefulness | 3 | 2018 | 59 | 0.340 |
Why?
|
| Aged | 21 | 2021 | 10054 | 0.330 |
Why?
|
| Neurosurgical Procedures | 4 | 2019 | 121 | 0.310 |
Why?
|
| Severity of Illness Index | 8 | 2017 | 1083 | 0.300 |
Why?
|
| House Calls | 2 | 2017 | 28 | 0.290 |
Why?
|
| Stereotaxic Techniques | 4 | 2021 | 36 | 0.290 |
Why?
|
| Fingers | 3 | 2017 | 42 | 0.270 |
Why?
|
| Middle Aged | 19 | 2021 | 13076 | 0.270 |
Why?
|
| Humans | 34 | 2024 | 54304 | 0.270 |
Why?
|
| Male | 25 | 2023 | 27335 | 0.260 |
Why?
|
| Dopamine Agents | 2 | 2014 | 19 | 0.260 |
Why?
|
| Female | 25 | 2023 | 28457 | 0.250 |
Why?
|
| Tremor | 2 | 2013 | 18 | 0.240 |
Why?
|
| Delayed-Action Preparations | 2 | 2023 | 50 | 0.200 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2021 | 1222 | 0.200 |
Why?
|
| Evidence-Based Medicine | 1 | 2012 | 275 | 0.200 |
Why?
|
| Drug Combinations | 2 | 2023 | 128 | 0.200 |
Why?
|
| Median Nerve | 1 | 2020 | 8 | 0.190 |
Why?
|
| Aged, 80 and over | 9 | 2020 | 3430 | 0.190 |
Why?
|
| Radial Nerve | 1 | 2020 | 4 | 0.190 |
Why?
|
| Electric Stimulation Therapy | 1 | 2020 | 26 | 0.190 |
Why?
|
| Activities of Daily Living | 2 | 2019 | 204 | 0.180 |
Why?
|
| Hand | 1 | 2020 | 58 | 0.180 |
Why?
|
| Movement Disorders | 1 | 2019 | 19 | 0.180 |
Why?
|
| Brain Mapping | 1 | 2021 | 250 | 0.180 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2021 | 1616 | 0.180 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 1 | 2019 | 8 | 0.170 |
Why?
|
| Actigraphy | 1 | 2019 | 22 | 0.170 |
Why?
|
| Monitoring, Ambulatory | 1 | 2019 | 11 | 0.170 |
Why?
|
| Peripheral Nerves | 1 | 2019 | 51 | 0.170 |
Why?
|
| Drug Administration Schedule | 2 | 2016 | 401 | 0.160 |
Why?
|
| Surgery, Computer-Assisted | 2 | 2015 | 53 | 0.160 |
Why?
|
| Monoamine Oxidase Inhibitors | 1 | 2017 | 8 | 0.150 |
Why?
|
| Metabolic Diseases | 1 | 2017 | 44 | 0.150 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2016 | 17 | 0.140 |
Why?
|
| Dyskinesia, Drug-Induced | 1 | 2016 | 23 | 0.140 |
Why?
|
| Lung | 1 | 2019 | 507 | 0.140 |
Why?
|
| Remote Consultation | 1 | 2016 | 29 | 0.140 |
Why?
|
| Videoconferencing | 1 | 2016 | 40 | 0.140 |
Why?
|
| Dementia | 1 | 2017 | 150 | 0.140 |
Why?
|
| Selegiline | 1 | 2015 | 4 | 0.130 |
Why?
|
| Medical Futility | 1 | 2015 | 12 | 0.130 |
Why?
|
| Adult | 9 | 2023 | 14189 | 0.130 |
Why?
|
| Dopamine Agonists | 1 | 2014 | 9 | 0.130 |
Why?
|
| Administration, Oral | 1 | 2016 | 461 | 0.130 |
Why?
|
| Serotonin 5-HT2 Receptor Agonists | 1 | 2013 | 8 | 0.120 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 426 | 0.120 |
Why?
|
| Disease Progression | 1 | 2017 | 915 | 0.120 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2014 | 172 | 0.120 |
Why?
|
| Urea | 1 | 2013 | 83 | 0.120 |
Why?
|
| Electrodes, Implanted | 3 | 2021 | 29 | 0.120 |
Why?
|
| Consumer Product Safety | 1 | 2013 | 22 | 0.110 |
Why?
|
| Piperidines | 1 | 2013 | 103 | 0.110 |
Why?
|
| Alzheimer Disease | 1 | 2017 | 369 | 0.110 |
Why?
|
| Sensation Disorders | 1 | 2012 | 14 | 0.110 |
Why?
|
| Polysaccharides | 1 | 2013 | 57 | 0.110 |
Why?
|
| Prospective Studies | 4 | 2021 | 2604 | 0.110 |
Why?
|
| Brain | 1 | 2021 | 1391 | 0.110 |
Why?
|
| Psychotic Disorders | 1 | 2013 | 143 | 0.110 |
Why?
|
| Longitudinal Studies | 3 | 2017 | 742 | 0.100 |
Why?
|
| Postural Balance | 1 | 2012 | 61 | 0.100 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2012 | 36 | 0.100 |
Why?
|
| Accidental Falls | 1 | 2012 | 98 | 0.100 |
Why?
|
| Telemedicine | 1 | 2017 | 457 | 0.100 |
Why?
|
| Canada | 2 | 2014 | 104 | 0.090 |
Why?
|
| Quality of Life | 3 | 2018 | 922 | 0.080 |
Why?
|
| Statistics, Nonparametric | 2 | 2014 | 230 | 0.080 |
Why?
|
| Myasthenia Gravis | 1 | 2008 | 17 | 0.080 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 2389 | 0.080 |
Why?
|
| Retrospective Studies | 5 | 2021 | 6462 | 0.080 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2008 | 150 | 0.070 |
Why?
|
| Time Factors | 3 | 2017 | 3207 | 0.070 |
Why?
|
| Feasibility Studies | 2 | 2017 | 398 | 0.070 |
Why?
|
| Physicians | 2 | 2019 | 244 | 0.060 |
Why?
|
| Neuropsychological Tests | 2 | 2017 | 363 | 0.060 |
Why?
|
| Benzothiazoles | 1 | 2023 | 11 | 0.060 |
Why?
|
| Research | 1 | 2023 | 116 | 0.060 |
Why?
|
| Animals | 1 | 2016 | 14402 | 0.050 |
Why?
|
| Young Adult | 2 | 2020 | 4313 | 0.050 |
Why?
|
| Respiratory Function Tests | 1 | 2019 | 98 | 0.040 |
Why?
|
| Microelectrodes | 1 | 2019 | 21 | 0.040 |
Why?
|
| Wrist | 1 | 2019 | 16 | 0.040 |
Why?
|
| Lung Diseases | 1 | 2019 | 86 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2019 | 195 | 0.040 |
Why?
|
| United States | 2 | 2014 | 5204 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2019 | 325 | 0.040 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2016 | 25 | 0.040 |
Why?
|
| Maintenance Chemotherapy | 1 | 2016 | 48 | 0.040 |
Why?
|
| Quality of Health Care | 1 | 2017 | 218 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2017 | 303 | 0.030 |
Why?
|
| Hypotension, Orthostatic | 1 | 2014 | 4 | 0.030 |
Why?
|
| Caregivers | 1 | 2017 | 240 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2014 | 91 | 0.030 |
Why?
|
| Sleep | 1 | 2015 | 188 | 0.030 |
Why?
|
| Proprioception | 1 | 2013 | 9 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2014 | 189 | 0.030 |
Why?
|
| Research Design | 1 | 2016 | 356 | 0.030 |
Why?
|
| Sex Characteristics | 1 | 2015 | 213 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 1143 | 0.030 |
Why?
|
| Meningioma | 1 | 2013 | 43 | 0.030 |
Why?
|
| Internet | 1 | 2016 | 275 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2018 | 1547 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 638 | 0.030 |
Why?
|
| Psychomotor Performance | 1 | 2013 | 156 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2013 | 634 | 0.030 |
Why?
|
| Sex Factors | 1 | 2014 | 766 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2012 | 103 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2014 | 580 | 0.030 |
Why?
|
| Walking | 1 | 2012 | 110 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 1294 | 0.020 |
Why?
|
| Receptors, Cholinergic | 1 | 2008 | 16 | 0.020 |
Why?
|
| Antibodies | 1 | 2008 | 178 | 0.020 |
Why?
|